Allergan acquires new filler brands

Allergan Aesthetics is to acquire an additional range of dermal fillers to join Juvéderm in a new deal with Isreali company Luminera. 

The privately held aesthetics company is selling its full dermal filler portfolio and R&D pipeline to Allergan Aesthetics. 

This includes brands Crystalys, Hydryalix and Hydryal, a mix of HA dermal fillers and CaHA (calcium hydroxyapatite)-based fillers commercialised across several markets.

However, Luminera's key focus for the future is HArmonyCa, a dermal filler intended for facial soft tissue augmentation comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.

HArmonyCa is currently commercially available in Israel and Brazil.

"The addition of the Luminera assets adds innovative technology, complementing our leading Juvéderm filler franchise,” said Carrie Strom, senior vice president at AbbVie, and president, Global Allergan Aesthetics.

“We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world.”

Luminera chairman Dadi Segal added, "We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people and products and a more expanded offering for our customers. This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company."

Allergan has partnered with SkinBetter Science on a project to encourage racial equailty in aesthetics.